TuBerculosis Vaccine Initiative (TBVI)

The TB vaccine development pathway

Recently Tuberculosis has published the article The TB vaccine development pathway – An innovative approach to accelerating global TB vaccine development. The publication emphasizes the importance of a diverse TB vaccine pipeline to address the TB-specific challenges. Individual vaccine candidates must be advanced rationally and the global pipeline must be managed in the most nimble and resource-efficient way, especially in the current constrained funding environment.

Read More →

The European Investment Bank provides €30 million loan to accelerate TB vaccine development

The European Investment Bank (EIB) agreed a €30 million loan with Vakzine Projekt Management GmbH (VPM), the German subsidiary of Serum Institute of India Pvt. Ltd. The loan will help VPM to perform the priMe trial. The priMe project contains a multicentre phase III double-blind, randomised, controlled study to evaluate the efficacy and safety of VPM1002 in comparison to the baccille Calmette–Guérin (BCG) vaccine. Vaccine research and development for the project will be carried out by VPM and the clinical trials will be scaled up in several high-burden sub-Saharan African countries.

Read More →

New live attenuated TB vaccine is safe and shows a distinct, dose dependent immune response in a Phase 1b trial in newborns

Biofabri, the University of Zaragoza, the South African Tuberculosis Vaccine Initiative (SATVI) and TB Vaccine Initiative (TBVI) announced the results of a Phase 1b trial of the new live attenuated TB vaccine ‘MTBVAC’ at the 5th Global Forum on TB vaccines, held on 20-23 February 2018 in New Delhi, India.

Read More →

MTBVAC will move to Phase 2 trials in 2018

The new Spanish TB vaccine MTBVAC has received 12 million euros to carry out Phase 2a trials in new-borns and in adults in South Africa.

Read More →

TBVAC2020 review article now online

TBVAC2020 (a European consortium of TB R&D partners led by TBVI and funded by the EC) gives an update on its progress towards the development of new, safe and affordable TB vaccines – essential to control the TB epidemic and combat AMR.

Read More →

European researchers identify a mechanism of protection of the new TB vaccine MTBVAC

Researchers at the University of Zaragoza (belonging to CIBERES) and the biopharmaceutical vaccine company Biofabri in Porrino, Spain in partnership with the TuBerculosis Vaccine Initiative (TBVI) are developing a new TB vaccine, MTBVAC. MTBVAC, a live attenuated M.tuberculosis vaccine, has been shown to provide improved protection as compared to BCG and the mechanism behind this greater efficacy has been hypothesized to be due to the ability of MTBVAC to present a wider collection of antigens of M. tuberculosis.

Read More →

Presentations TBVI symposium: TB vaccines and immunity

On 3 February 2016 the TuBerculosis Vaccine Initiative (TBVI) organised the symposium: TB vaccines and immunity.

Read More →

TB vaccine candidate shows excellent safety and promising immunogenicity

Lausanne / Zaragoza / Madrid / Porriño / Lelystad, 17 November 2016 – For the first time, a live-attenuated tuberculosis vaccine – MTBVAC – has been evaluated in humans. MTBVAC – evaluated in 36 human volunteers with no signs of previous exposure to M. tuberculosis – showed excellent safety and promising immunogenicity profiles. The results of this clinical trial, conducted in Lausanne, were published yesterday in the journal THE LANCET Respiratory Medicine. Following this promising evaluation, a subsequent study that will evaluate safety and immunogenicity in humans in an endemic setting has recently started in South Africa.

Read More →

24.6 million euros for TB vaccine R&D

The TBVI consortium has been granted 24.6 million euros from the European Commission H2020 framework programme (€18.2 mln.) and several institutions as well as national governments outside the EC, among others Switzerland, South Korea and Australia. With this grant the new TBVAC2020 project will be funded, so TBVI can continue its efforts to discover and develop new tuberculosis vaccines.

Read More →

New molecular basis of attenuation and immunogenicity of the tuberculosis vaccine candidate MTBVAC described

The tuberculosis vaccine candidate MTBVAC is the only vaccine in clinical trials based on an attenuated Mycobacterium tuberculosis strain of human origin. In various animal models, MTBVAC confers a similar attenuation and greater immunity than the current BCG vaccine against tuberculosis. BCG is a Mycobacterium bovis derivative, isolated from cows in the early twentieth century, which does not protect against respiratory forms of tuberculosis. MTBVAC is developed by TBVI’s research partner University of Zaragoza in collaboration with biopharmaceutical company Biofabri.

Read More →

Page 1 of 3 · Total posts: 10

1 2 Last→